Bio-techne Corporation

Jose Fernando Bazan

Christopher Carlin Valley

Vassilios Kalabokis

Guoping Wu

Jinghua Wang

Christine Goetz

Birte Aggeler

Jody Bonnevier

Christopher Hammerbeck

Described herein are polyclonal and monoclonal antibodies that binds to VSIG3, compounds that modulate the interaction of VISTA and VSIG3, and methods of making and using the polyclonal and monoclonal antibodies and compounds. Also described herein are methods that include modulating the interaction of VISTA and VSIG3 by introducing a compound that modulates the interaction of VISTA and SIG3.

Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using

The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy

Growing community of inventors

Stillwater, MN, United States of America

Jose Fernando Bazan